Oral levosimendan in patients with severe chronic heart failure --the PERSIST study (Q38572099)

4 September 2017

title

Oral levosimendan in patients with severe chronic heart failure --the PERSIST study (English)

1 reference

4 September 2017

main subject

chronic heart failure

1 reference

3

Jaan Eha

1 reference

4 September 2017

Markku S Nieminen

1

1 reference

4 September 2017

John G F Cleland

2

1 reference

4 September 2017

Yuri Belenkov

4

1 reference

4 September 2017

Matti Kivikko

5

1 reference

4 September 2017

Pentti Põder

6

1 reference

4 September 2017

Toni Sarapohja

7

1 reference

4 September 2017

language of work or name

1 reference

21 October 2008

1 reference

European Journal of Heart Failure

4 September 2017

published in

1 reference

4 September 2017

volume

10

1 reference

4 September 2017

issue

12

1 reference

4 September 2017

page(s)

1246-1254

1 reference

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Cardiac resynchronization in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

The effect of cardiac resynchronization on morbidity and mortality in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Plasma natriuretic peptide levels and the risk of cardiovascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

Levosimendan protects against experimental endotoxemic acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.09.006

10.1016/J.EJHEART.2008.09.006

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference